HOOK News and Press, HOOKIPA Pharma Inc. From 03/24/22

Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pem...

OTCQX:CCHWF, CIH, OTCQX:CWBHF, DRI, FDS, HOOK, OTCQX:JUSHF, KC, MOMO, NEOG, SNX, TFFP, TITN, TMDI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

Hoopika Pharma (NASDAQ:HOOK) has promoted Klaus Orlinger, Ph.D. to Chief Scientific Officer, most recently serving as Executive Vice President, Research. Since joining HOOKIPA in February 2012, Klaus has played a leading role in driving HOOKIPA’s arenaviral platform to the clinic ...

NEW YORK and VIENNA, Austria, March 22, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Klaus Orlinger, Ph.D. has been promoted to ...

NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full yea...

Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitors Preclinical data suggest synergy of arenaviral immunotherapy with 4-1BB agonists or cell therapy, resulting in better tumor control...

Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...

Karyopharm Therapeutics (NASDAQ:KPTI) -29% after US Regulatory update on Selinexor in advanced or recurrent endometrial cancer. GoHealth (NASDAQ:GOCO) -24% on expecting Q4 revenue below estimates. Bright Health (NYSE:BHG) -10% on Q4 earnings release. Telefonaktie...

HOOKIPA Pharma (NASDAQ:HOOK) trades 15.1% down premarket after pricing its underwritten public offering of 21.7M shares and 15.8K shares of its non-voting Series A-1 convertible preferred stock. The public offering price of each share of common stock is $2.00 and the ...

NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 21,700,000 shares of it...